Hangzhou DAC Biotech Co., Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hangzhou DAC Biotech Co., Ltd - overview
Established
2012
Location
Hangzhou, Zhejiang, China
Primary Industry
Pharmaceuticals
About
Based in Hangzhou, China and established in 2012, Hangzhou DAC Biotech Co. , Ltd is a biotechnology company that engages in the research and development of conjugate of monoclonal antibody and small molecular cytotoxic drug. The company’s core technical team includes 5 overseas returnees, 36 domestically graduated doctors and masters, and more than 40 bachelor’s degree professional and technical personnel. The company mainly develops antibody-drug conjugates, including tubulin inhibitors, DNA groove inhibitors, DNA alkylation and RNA polymerase inhibitors.
It targets tumor cells through antibodies, and releases cytotoxic drugs through chemical or enzymatic action at the tumor to achieve precise killing of tumor cells.
Current Investors
Zhejiang Huahai Pharmaceutical, Betta Pharmaceuticals, ZJKF Capital Management
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.dacbiotech.com
Verticals
HealthTech
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.